Dentaltech company  Biolux Technology has raised €4.26 million  (CHF 4 million) Seed funding from redalpine and Revere Partners.

Biolux Technology develops light-accelerated orthodontics. Its FDA-cleared, patented, and commercially successful flagship product, OrthoPulse uses near-infrared light therapy to safely and effectively accelerate tooth movement, reducing treatment times by up to 50 per cent and treatment discomfort. It also tackles a critical issue in patient care – longer treatments often lead to reduced compliance and more expensive, time-consuming refinements. 

According to Marcel Pordes, CEO of Biolux Technology:

“We are committed to providing patients with faster, more efficient treatment options and ensuring orthodontists have the tools they need to deliver exceptional care.”

Daniel Dillinger, Principal at redalpine, shared the firm’s commitment to “partnering with the Biolux team as they enter the next growth phase, further enhancing the state-of-the-art user experience to support their rapid scaling and expansion in the US market.”

Biolux Technology also announced the appointment of Raphael Pascaud as Chairman of the Board. 

With this new funding, Biolux Technology will accelerate the development of OrthoPulse® launch a smart digital platform offering real-time monitoring and treatment optimisation for both orthodontists and patients.

Lead image: Biolux Technology. Photo: uncredited.